| Heema Kaul, MD | |
|
360 Merrimack St, Bldg 9, Entrance I, Lawrence, MA 01843-1740 | |
| (978) 688-6182 | |
| (978) 689-0731 |
| Full Name | Heema Kaul |
|---|---|
| Gender | Female |
| Speciality | Ophthalmology |
| Experience | 19 Years |
| Location | 360 Merrimack St, Lawrence, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891961736 | NPI | - | NPPES |
| 110087423A | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 242472 (Massachusetts) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tallman Eye Associates Pc | 3577501063 | 17 |
| Tallman Eye Whittier | 3678982352 | 8 |
| Tallman Eye Bidco | 7315236866 | 10 |
| Tallman Eye Associates Pc | 3577501063 | 17 |
News Archive
Agilent Technologies Inc. (NYSE:A) and Applied Biosystems, part of Life Technologies Corp. (NASDAQ:LIFE), today introduced the Agilent SureSelect Target Enrichment System, which is optimized for the SOLiD™ System, a next-generation advanced genomic analysis sequencing platform.
Health Affairs: Chronic Conditions Account For Rise In Medicare Spending From 1987 To 2006 - "Medicare beneficiaries' medical needs, and where beneficiaries undergo treatment, have changed dramatically over the past two decades." For example, the authors write, "heart disease ranked first among the top-ten conditions in terms of attributable share of growth from 1987 to 1997, accounting for nearly 14 percent of the increase in Medicare spending."
The nanoparticle targets only leukemic cells and therefore would reduce the severe adverse effects of current treatments.
Global manufacturing of biopharmaceuticals has increased significantly over the last decade due to a number of reasons. Biopharmaceuticals offer several advantages such as highly effective and potent action, fewer side effects and the potential to actually cure diseases rather than merely treat the symptoms.
› Verified 1 days ago
| Entity Name | Tallman Eye Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194833467 PECOS PAC ID: 3577501063 Enrollment ID: O20050425000836 |
News Archive
Agilent Technologies Inc. (NYSE:A) and Applied Biosystems, part of Life Technologies Corp. (NASDAQ:LIFE), today introduced the Agilent SureSelect Target Enrichment System, which is optimized for the SOLiD™ System, a next-generation advanced genomic analysis sequencing platform.
Health Affairs: Chronic Conditions Account For Rise In Medicare Spending From 1987 To 2006 - "Medicare beneficiaries' medical needs, and where beneficiaries undergo treatment, have changed dramatically over the past two decades." For example, the authors write, "heart disease ranked first among the top-ten conditions in terms of attributable share of growth from 1987 to 1997, accounting for nearly 14 percent of the increase in Medicare spending."
The nanoparticle targets only leukemic cells and therefore would reduce the severe adverse effects of current treatments.
Global manufacturing of biopharmaceuticals has increased significantly over the last decade due to a number of reasons. Biopharmaceuticals offer several advantages such as highly effective and potent action, fewer side effects and the potential to actually cure diseases rather than merely treat the symptoms.
› Verified 1 days ago
| Entity Name | Tallman Eye Bidco |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033419072 PECOS PAC ID: 7315236866 Enrollment ID: O20160523001756 |
News Archive
Agilent Technologies Inc. (NYSE:A) and Applied Biosystems, part of Life Technologies Corp. (NASDAQ:LIFE), today introduced the Agilent SureSelect Target Enrichment System, which is optimized for the SOLiD™ System, a next-generation advanced genomic analysis sequencing platform.
Health Affairs: Chronic Conditions Account For Rise In Medicare Spending From 1987 To 2006 - "Medicare beneficiaries' medical needs, and where beneficiaries undergo treatment, have changed dramatically over the past two decades." For example, the authors write, "heart disease ranked first among the top-ten conditions in terms of attributable share of growth from 1987 to 1997, accounting for nearly 14 percent of the increase in Medicare spending."
The nanoparticle targets only leukemic cells and therefore would reduce the severe adverse effects of current treatments.
Global manufacturing of biopharmaceuticals has increased significantly over the last decade due to a number of reasons. Biopharmaceuticals offer several advantages such as highly effective and potent action, fewer side effects and the potential to actually cure diseases rather than merely treat the symptoms.
› Verified 1 days ago
| Entity Name | Tallman Eye Whittier |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639768229 PECOS PAC ID: 3678982352 Enrollment ID: O20210510001869 |
News Archive
Agilent Technologies Inc. (NYSE:A) and Applied Biosystems, part of Life Technologies Corp. (NASDAQ:LIFE), today introduced the Agilent SureSelect Target Enrichment System, which is optimized for the SOLiD™ System, a next-generation advanced genomic analysis sequencing platform.
Health Affairs: Chronic Conditions Account For Rise In Medicare Spending From 1987 To 2006 - "Medicare beneficiaries' medical needs, and where beneficiaries undergo treatment, have changed dramatically over the past two decades." For example, the authors write, "heart disease ranked first among the top-ten conditions in terms of attributable share of growth from 1987 to 1997, accounting for nearly 14 percent of the increase in Medicare spending."
The nanoparticle targets only leukemic cells and therefore would reduce the severe adverse effects of current treatments.
Global manufacturing of biopharmaceuticals has increased significantly over the last decade due to a number of reasons. Biopharmaceuticals offer several advantages such as highly effective and potent action, fewer side effects and the potential to actually cure diseases rather than merely treat the symptoms.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Heema Kaul, MD 360 Merrimack St, Bldg 9, Entrance I, Lawrence, MA 01843-1740 Ph: (978) 688-6182 | Heema Kaul, MD 360 Merrimack St, Bldg 9, Entrance I, Lawrence, MA 01843-1740 Ph: (978) 688-6182 |
News Archive
Agilent Technologies Inc. (NYSE:A) and Applied Biosystems, part of Life Technologies Corp. (NASDAQ:LIFE), today introduced the Agilent SureSelect Target Enrichment System, which is optimized for the SOLiD™ System, a next-generation advanced genomic analysis sequencing platform.
Health Affairs: Chronic Conditions Account For Rise In Medicare Spending From 1987 To 2006 - "Medicare beneficiaries' medical needs, and where beneficiaries undergo treatment, have changed dramatically over the past two decades." For example, the authors write, "heart disease ranked first among the top-ten conditions in terms of attributable share of growth from 1987 to 1997, accounting for nearly 14 percent of the increase in Medicare spending."
The nanoparticle targets only leukemic cells and therefore would reduce the severe adverse effects of current treatments.
Global manufacturing of biopharmaceuticals has increased significantly over the last decade due to a number of reasons. Biopharmaceuticals offer several advantages such as highly effective and potent action, fewer side effects and the potential to actually cure diseases rather than merely treat the symptoms.
› Verified 1 days ago
Dr. Monika Singh, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 360 Merrimack St, Bldg 9, Entrance I, Lawrence, MA 01843 Phone: 978-688-6182 Fax: 978-689-0731 | |
Cynthia L Deangelis, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 360 Merrimack St, Bldg 9, Entrance I, Lawrence, MA 01843 Phone: 978-688-6182 Fax: 978-689-0731 | |
Thomas P Pappavaselio, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 360 Merrimack St, Bldg 9, Entrance I, Lawrence, MA 01843 Phone: 978-688-6185 Fax: 978-689-0731 | |
Robert O. Kwon, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 360 Merrimack St, Bldg 9, Entrance I, Lawrence, MA 01843 Phone: 978-688-6182 Fax: 978-689-0731 | |
Dr. Davinder S Nagra, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 280 Haverhill St, Lawrence, MA 01840 Phone: 978-685-5366 Fax: 978-685-4867 | |
Carter B Tallman, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 360 Merrimack St, Bldg 9, Entrance I, Lawrence, MA 01843 Phone: 978-688-6182 Fax: 978-689-0731 | |
Samuel D Allen, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 360 Merrimack St, Bldg 9, Entrance I, Lawrence, MA 01843 Phone: 978-688-6182 Fax: 978-689-0731 |